Brain ageing in schizophrenia: evidence from 26 international cohorts via the ENIGMA Schizophrenia consortium

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • University of Bath
  • University of Melbourne
  • ORYGEN Youth Health
  • Amsterdam University Medical Centers (UMC)
  • Complutense University
  • CIBER - Centro de Investigación Biomédica en Red
  • University of Bari
  • Ludwig-Maximilians-Universität München (LMU)
  • Hospital Universitario Marques de Valdecilla
  • IRCCS Fondazione Santa Lucia - Roma
  • Universität Basel
  • Universität zu Lübeck
  • University of New South Wales
  • Neuroscience Research Australia
  • University of New Mexico
  • Centre Hospitalier des Quatre Villes
  • Georgia Institute of Technology
  • Monash University
  • University of Queensland
  • Jeonbuk National University
  • Hospital Universitario Virgen del Rocio
  • University of Galway
  • University of Stellenbosch
  • Georgia State University
  • University of California at San Diego
  • VA Medical Center
  • Sisters Hospitallers Research Foundation
  • Universität Zürich
  • Hospital Benito Menni
  • Seoul National University
  • Westfälische Wilhelms-Universität Münster
  • University of Newcastle
  • Hunter Medical Research Institute (HMRI)
  • University of Southern California
  • Universität Genf
  • Russian Academy of Medical Sciences
  • McGill University
  • University of Maryland, Baltimore
  • Maastricht University
  • National College of Ireland

Abstract

Schizophrenia (SZ) is associated with an increased risk of life-long cognitive impairments, age-related chronic disease, and premature mortality. We investigated evidence for advanced brain ageing in adult SZ patients, and whether this was associated with clinical characteristics in a prospective meta-analytic study conducted by the ENIGMA Schizophrenia Working Group. The study included data from 26 cohorts worldwide, with a total of 2803 SZ patients (mean age 34.2 years; range 18–72 years; 67% male) and 2598 healthy controls (mean age 33.8 years, range 18–73 years, 55% male). Brain-predicted age was individually estimated using a model trained on independent data based on 68 measures of cortical thickness and surface area, 7 subcortical volumes, lateral ventricular volumes and total intracranial volume, all derived from T1-weighted brain magnetic resonance imaging (MRI) scans. Deviations from a healthy brain ageing trajectory were assessed by the difference between brain-predicted age and chronological age (brain-predicted age difference [brain-PAD]). On average, SZ patients showed a higher brain-PAD of +3.55 years (95% CI: 2.91, 4.19; I2 = 57.53%) compared to controls, after adjusting for age, sex and site (Cohen’s d = 0.48). Among SZ patients, brain-PAD was not associated with specific clinical characteristics (age of onset, duration of illness, symptom severity, or antipsychotic use and dose). This large-scale collaborative study suggests advanced structural brain ageing in SZ. Longitudinal studies of SZ and a range of mental and somatic health outcomes will help to further evaluate the clinical implications of increased brain-PAD and its ability to be influenced by interventions.

Details

OriginalspracheEnglisch
Seiten (von - bis)1201-1209
Seitenumfang9
FachzeitschriftMolecular psychiatry
Jahrgang28
Ausgabenummer3
PublikationsstatusVeröffentlicht - März 2023
Peer-Review-StatusJa

Externe IDs

PubMed 36494461
ORCID /0000-0003-2132-4445/work/150328106